Vimarsana
Biggest News Aggregation in the World

Selected Important Safety News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Selected Important Safety. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Selected Important Safety Today - Breaking & Trending Today

Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma - Vimarsana News

Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Published: May 1, 2024

These OS results build on positive data previously reported from KEYNOTE-811 that supported its FDA-approved indication ...

Source: marketscreener.com
Related Topics:
United StatesMerck Research LaboratoriesDrug AdministrationMerck Co IncEuropean Society For Medical OncologyStatement Of Merck Co IncExchange CommissionMarjorie GreenMerck ResearchEuropean SocietyMedical OncologyImportant Safety InformationSelected Important SafetyFatal Immune Mediated AdverseSingle AgentThyroid DisordersWhich Can Present With Diabetic KetoacidosisNervous SystemConnective TissuePatients With Multiple MyelomaNeck Squamous Cell CancerBacillus Calmette GuerinMismatch Repair Deficient CancerMismatch Repair Deficient Colorectal CancerLooking Statement
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer - Vimarsana News

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer

Published: April 4, 2024

Merck , known as MSD outside of the United States and Canada, today announced it has initiated a Phase 3 clinical trial evaluating MK-1084, an investigational oral selective KRAS G12C inhibitor, in...

Source: marketscreener.com
Related Topics:
United StatesMerck Research LaboratoriesEuropean Society For Medical OncologyExchange CommissionStatement Of Merck Co IncTaiho Pharmaceutical CoMerck Co IncAstex Pharmaceuticals United KingdomOtsuka Pharmaceutical Co LtdMarjorie GreenMerck ResearchEuropean SocietyMedical OncologyTaiho PharmaceuticalAstex PharmaceuticalsUnited KingdomSelected Important SafetyImportant Safety InformationFatal Immune Mediated AdverseWhich Can Present With DiabeticNervous SystemConnective TissuePatients With MultipleNeck Squamous CellBacillus Calmette Guerin
European Commission Approves Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults -March 28, 2024 at 06:46 am EDT - Vimarsana News

European Commission Approves Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults -March 28, 2024 at 06:46 am EDT

Published: March 28, 2024

Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results and represents the sixth approval for KEYTRUDA in lung cancer in...

Source: marketscreener.com
Related Topics:
United StatesSolange PetersExchange CommissionMerck Research LaboratoriesStatement Of Merck Co IncCentre Hospitalier Universitaire VaudoisCommittee For Medicinal Products HumanMerck Co IncEuropean CommissionMedicinal ProductsHuman UseMarjorie GreenMerck ResearchAmerican Joint CommitteeCancer Staging ManualSelected Important SafetyImportant Safety InformationFatal Immune Mediated AdverseWhich Can Present With DiabeticNervous SystemConnective TissuePatients With MultipleNeck Squamous CellBacillus Calmette GuerinMismatch Repair Deficient
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence - Vimarsana News

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence

Published: February 23, 2024

Opinion granted based on positive overall survival and event-free survival results from the Phase 3 KEYNOTE-671 trial First opinion to be granted for an anti-PD-1/L1 therapy in resectable non-small...

Source: marketscreener.com
Related Topics:
United StatesStatement Of Merck Co IncEuropean CommissionEuropean UnionAmerican Joint Committee On CancerMerck Research LaboratoriesExchange CommissionMerck Co IncEuropean Medicines AgencyMedicinal ProductsHuman UseAmerican Joint CommitteeMarjorie GreenMerck ResearchSelected Important SafetyImportant Safety InformationFatal Immune Mediated AdverseWhich Can Present With DiabeticNervous SystemConnective TissuePatients With MultipleNeck Squamous CellBacillus Calmette Guerin UnresponsiveMismatch Repair DeficientMismatch Repair Deficient Colorectal
Merck's KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy -January 27, 2024 at 10:01 am EST - Vimarsana News

Merck's KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy -January 27, 2024 at 10:01 am EST

Published: January 27, 2024

KEYNOTE-564 is the first Phase 3 trial to demonstrate superior overall survival with adjuvant therapy compared to placebo in patients with RCC Late-breaking OS results selected for the official...

Source: marketscreener.com
Related Topics:
United StatesTonik ChoueiriNancy KohlbergHarvard Medical SchoolExchange CommissionAsco Gu Press ProgramDana Farber Cancer InstituteLank CenterAmerican Society Of Clinical OncologyStatement Of Merck Co IncMerck Research LaboratoriesEuropean UnionAkeso IncMerck Co IncClinical OncologyCancers SymposiumGenitourinary OncologyHarvard MedicalMarjorie GreenMerck ResearchPositive ScoreSelected Important SafetyImportant Safety InformationFatal Immune Mediated AdverseWhich Can Present With Diabetic